CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionJanus Henderson Group Plc
Latest Disclosed Ownership40,274 shares
Latest Disclosed Value $ 1,916,438
Janus Henderson Group Plc reports 15.82% increase in ownership of CRSP / CRISPR Therapeutics AG

On May 18, 2026 - Janus Henderson Group Plc filed a 13F-HR/A form disclosing ownership of 40,274 shares of CRISPR Therapeutics AG (US:CRSP) valued at $1,915,834 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 34,774 shares of CRISPR Therapeutics AG. This represents a change in shares of 15.82% during the quarter. The current value of the position is $2,293,604 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-18 2026-03-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 40,274 5,500 15.82 1,916 5.16 0.0003
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 40,274 5,500 1,916 0.0004
2026-02-17 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 34,774 0 0.00 1,823 -19.17 0.0008
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 34,774 0 0.00 2,254 33.37 0.0010
2025-08-14 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 34,774 0 0.00 1,691 31.42 0.0008
2025-05-15 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 34,774 0 0.00 1,286 -6.06 0.0007
2025-02-14 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 34,774 0 0.00 1,369 -16.22 0.0007
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 34,774 0 0.00 1,635 -12.90 0.0008
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 34,774 0 0.00 1,876 -20.81 0.0010
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 34,774 0 0.00 2,370 8.87 0.0013
2024-02-14 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 34,774 0 0.00 2,177 37.90 0.0013
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 34,774 0 0.00 1,579 -19.16 0.0010
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 34,774 0 0.00 1,953 24.09 0.0012
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 34,774 21,512 162.21 1,574 191.84 0.0010
2023-02-14 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 13,262 0 0.00 539 -37.83 0.0004
2023-01-13 2022-09-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 13,262 -1,600 -10.77 867 -3.99 0.0006
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 13,262 -1,600 867 0.0006
2022-08-15 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 14,862 2,989 25.17 903 21.05 0.0006
2022-05-16 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 11,873 11,873 746 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.